Briciclib(ON 013105,ON 014185)

Cas No.:	865783-99-9
Chemical Name:	Briciclib
Synonyms:	Briciclib;2-Methoxy-5-({[(E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfonyl}methy l)phenyl dihydrogen phosphate;Phenol, 2-Methoxy-5-[[[(1E)-2-(2,4,6-triMethoxyphenyl)ethenyl]sulfonyl]Methyl]-, 1-(dihydrogen phosphate);ON014185;ON-014185;WG93X96336;ON 014185;(E)-2-Methoxy-5-(((2,4,6-trimethoxystyryl)sulfonyl)methyl)phenyl dihydrogen phosphate;Briciclib [USAN:INN];Phenol, 2-methoxy-5-((((1E)-2-(2,4,6-trimethoxyphenyl)ethenyl)sulfonyl)methyl)-, 1-(dihydrogen phosphate);Briciclib (USAN/INN);Briciclib; ON 014185
SMILES:	S(/C(/[H])=C(\[H])/C1C(=C([H])C(=C([H])C=1OC([H])([H])[H])OC([H])([H])[H])OC([H])([H])[H])(C([H])([H])C1C([H])=C([H])C(=C(C=1[H])OP(=O)(O[H])O[H])OC([H])([H])[H])(=O)=O
Formula:	C19H23O10PS
M.Wt:	474.4187
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:

Briciclib is a water soluble derivative of ON 013100, and has the potential in targeting eIF4E for solid cancers.

In Vitro:

Briciclib has the potential in targeting eIF4E. Briciclib shows inhibitory activity against the proliferation of mantle cell leukemia (EKO-1 and MINO), breast (MCF7 and MDA-MB-231), gastric (AGS), and esophageal (OE19, OE33, and FLO-1) cancer cell lines with GI50s of 9.8-12.2 nM, and with no toxicity on normal endothelial cells. Briciclib dose-dependently reduces the expression of cyclin D1 and c-Myc in breast and MCL cancer cell lines within 8 hours[1].